行情

GKOS

GKOS

Glaukos
NYSE

实时行情|Nasdaq Last Sale

63.78
+1.08
+1.72%
盘后: 63.78 0 0.00% 16:52 11/15 EST
开盘
63.27
昨收
62.70
最高
64.27
最低
62.87
成交量
40.84万
成交额
--
52周最高
84.65
52周最低
50.60
市值
23.55亿
市盈率(TTM)
-120.9329
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GKOS 新闻

  • 汽油涨价引发大规模抗议 伊朗两天约千人被捕
  • 新浪美股.3小时前
  • 全球最大的IPO来了 沙特阿美IPO指导价敲定
  • 新浪财经综合.3小时前
  • 沙特阿美拟募资超240亿美元,整体估值达1.6万亿美元
  • 澎湃新闻.6小时前
  • 7000亿美元!金融业忽视女性每年付出的代价
  • 快科技.6小时前

更多

所属板块

医疗设备、用品及经销
+1.05%
医疗设备和用品
+1.69%

热门股票

名称
价格
涨跌幅

GKOS 简况

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
展开

Webull提供Glaukos Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。